Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Operating Expenses (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Operating Expenses for 14 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 29.28% to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.7 million through Dec 2025, up 32.04% year-over-year, with the annual reading at $56.5 million for FY2025, 65.64% up from the prior year.
  • Operating Expenses hit $19.8 million in Q4 2025 for Vistagen Therapeutics, down from $20.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $20.3 million in Q3 2025 to a low of $6.7 million in Q1 2021.
  • Historically, Operating Expenses has averaged $13.1 million across 5 years, with a median of $12.8 million in 2021.
  • Biggest five-year swings in Operating Expenses: surged 262.71% in 2021 and later tumbled 64.27% in 2023.
  • Year by year, Operating Expenses stood at $10.9 million in 2021, then decreased by 8.73% to $9.9 million in 2022, then fell by 16.6% to $8.3 million in 2023, then soared by 85.1% to $15.4 million in 2024, then grew by 29.28% to $19.8 million in 2025.
  • Business Quant data shows Operating Expenses for VTGN at $19.8 million in Q4 2025, $20.3 million in Q3 2025, and $16.0 million in Q2 2025.